Alaric DeArment

Reporter at Scrip

Featured in: Favicon

informa.com (+3) Favicon

forbes.com Favicon

medium.com Favicon

nydailynews.com Favicon

sun-sentinel.com Favicon

newrepublic.com Favicon

abovethelaw.com Favicon

medcitynews.com Favicon

geneticliteracyproject.org Favicon

dealbreaker.com + 6 more

Articles

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

1 day ago | insights.citeline.com | Joseph Haas |Sushmita Panda |Alaric DeArment

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFoundPlus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

1 week ago | insights.citeline.com | Sarah Karlin-Smith |Sarah Karlin-Smith |Mandy Jackson |Alaric DeArment

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review ProgramUpdates From Day 3 Of BIOHighlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

1 week ago | insights.citeline.com | Alaric DeArment

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa SuccessCEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

1 week ago | insights.citeline.com | Alaric DeArment

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor ProgressThe company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, ResistanceGilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: Carvykti Data Raise Possibility Of Myeloma CureJ&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology PlayerThe drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change PracticeAI, Biomarkers Could Help Predict Enhertu Toxicity Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

3 weeks ago | insights.citeline.com | Alaric DeArment

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week DataTakeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.